Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
Titel:
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
Auteur:
Usmani, Saad Z. Quach, Hang Mateos, MarĂa-Victoria Landgren, Ola Leleu, Xavier Siegel, David S. Weisel, Katja Yang, Hui Klippel, Zandra K. Zahlten-Kumeli, Anita Dimopoulos, Meletios A.